209 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
will follow subject to the start of dosing in the proof-of-concept trial. Adaptimmune will be responsible for the clinical proof-of-concept trial in head … & neck cancer and the supply of the vector for the manufacturing of uza-cel. Galapagos will be responsible for the delivery of fresh uza-cel product
8-K
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
will be responsible for the clinical proof-of-concept trial in head and neck cancer and the supply of the vector. Galapagos will be responsible for the manufacture … of dosing in the proof-of-concept trial. Each party to the Agreement is responsible for performing the activities allocated to it under the agreed
8-K
EX-10.1
f9j9oy
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.2
b51y5k6 is
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
aiizfylm7h3b99
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
al7rouawtf
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
j8n9kdqlxf0b29lkr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
reotjqc5t7x
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
dxifhrgkcze04ca2p6
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm